Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
| Ominto, Inc.OMNT · Entity 164576 | Director | December 08, 2016 | January 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,720 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 8,720 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 11,182 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
Ominto, Inc.
Report date December 08, 2016 · Filed January 12, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 90,000 |
Reported balance
After 2016-12-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-12-08 · Grant · Acquired 70,000 · Balance 90,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting. F3: Options vest over 30 month period. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 120,000 |
Reported balance
After 2016-12-08 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2016-12-08 · Grant · Acquired 30,000 · Balance 120,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors.
F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting.
F3: Options vest over 30 month period.
F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017.
F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date October 01, 2024 · Filed October 02, 2024
Section 16 reporting ended · disclosed 2024-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,533 |
Ending reported balance
After 2024-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-10-01 · Tax withholding · Disposed 331 · Balance 179,269 F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Row 2 · 2024-10-01 · Tax withholding · Disposed 616 · Balance 178,653 F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Row 3 · 2024-10-01 · Tax withholding · Disposed 662 · Balance 177,991 F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Row 4 · 2024-10-01 · Tax withholding · Disposed 458 · Balance 177,533 F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
Holding disclosure · report date 2024-10-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,600 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021.
F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022.
F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023.
F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2021 Filed Jul 12, 2021 19:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $90.65 | $54,390.00 |
DisclosureSEC source: 0001562180-21-004903 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,106 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $90.15 to $91.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 19:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-004903 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 17:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 231 | $95.99 | $22,173.69 |
DisclosureSEC source: 0001562180-21-004832 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,706 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 18:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-004156 · primarydocument.xml · derivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option vested with respect to 25% of the underline shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 18:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $92.31 | $55,383.00 |
DisclosureSEC source: 0001562180-21-004156 · primarydocument.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $92.00 to $92.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 18:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 826 | $91.04 | $75,200.44 |
DisclosureSEC source: 0001562180-21-004156 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,537 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $90.79 to $91.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 18:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,319 | $90.49 | $209,847.24 |
DisclosureSEC source: 0001562180-21-004156 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,363 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $89.78 to $90.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 18:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,255 | $89.03 | $111,730.77 |
DisclosureSEC source: 0001562180-21-004156 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,682 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $88.78 to $89.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 18:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-004156 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-003419 · primarydocument.xml · derivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option vested with respect to 25% of the underline shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $92.34 | $36,935.68 |
DisclosureSEC source: 0001562180-21-003419 · primarydocument.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $92.16 to $92.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,300 | $91.14 | $209,613.72 |
DisclosureSEC source: 0001562180-21-003419 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,337 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $90.65 to $91.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,455 | $89.81 | $130,667.73 |
DisclosureSEC source: 0001562180-21-003419 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,637 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $89.41 to $90.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 845 | $88.67 | $74,928.60 |
DisclosureSEC source: 0001562180-21-003419 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,092 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $88.31 to $89.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-003419 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-002782 · primarydocument.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option vested with respect to 25% of the underline shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 876 | $113.35 | $99,296.70 |
DisclosureSEC source: 0001562180-21-002782 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $113.05 to $113.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,900 | $112.56 | $213,864.38 |
DisclosureSEC source: 0001562180-21-002782 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,813 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $112.01 to $112.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,224 | $111.45 | $247,865.69 |
DisclosureSEC source: 0001562180-21-002782 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,713 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $111.00 to $111.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-002782 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:58 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 253 | $109.21 | $27,630.13 |
DisclosureSEC source: 0001562180-21-002603 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,937 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units - April 1,2021 Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · derivative · entry 8 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vests with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 942 | $99.28 | $93,521.85 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · nonDerivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,190 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F6 · price: This transaction was executed in multiple trades at prices ranging from $98.93 to $99.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,058 | $98.39 | $202,491.77 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,132 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F5 · price: This transaction was executed in multiple trades at prices ranging from $97.91 to $98.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,500 | $97.44 | $146,166.00 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,190 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $96.90 to $97.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $95.53 | $38,211.00 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,690 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $95.25 to $95.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 100 | $94.05 | $9,405.00 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,090 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020 Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 14:48 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-002171 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 347 shares acquired under the Employee Stock Purchase Plan. Read SEC document |
| February 11, 2021 Filed Feb 24, 2021 16:34 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 10,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001566 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,190 F1 · shares: 2021 Annual RSU grant - vesting Commencement date Jan-1-2021, 1/16th of the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · derivative · entry 8 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 100 | $116.93 | $11,693.00 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · nonDerivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 300 | $115.88 | $34,764.00 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.50 to $116.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $114.45 | $45,779.00 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,900 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.15 to $114.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,823 | $113.10 | $206,172.55 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $112.83 to $113.60 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,377 | $112.53 | $267,472.16 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,123 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $111.82 to $112.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 15:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-001019 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 17:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 36,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-000356 · primarydocument.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,977 Underlying: Common Stock · 36,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 17:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,198 | $92.01 | $110,230.98 |
DisclosureSEC source: 0001562180-21-000356 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $92.00 to $92.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 17:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 7,489 | $91.38 | $684,357.55 |
DisclosureSEC source: 0001562180-21-000356 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,698 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $91.00 to $91.94 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 17:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 27,313 | $90.29 | $2,466,011.56 |
DisclosureSEC source: 0001562180-21-000356 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,187 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.00 to $90.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 17:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 36,000 | $0.46 | $16,452.00 |
DisclosureSEC source: 0001562180-21-000356 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 17:15 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-21-000288 · primarydocument.xml · derivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F5 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 17:15 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,443 | $83.80 | $120,923.40 |
DisclosureSEC source: 0001562180-21-000288 · primarydocument.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $83.54 to $84.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 17:15 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,857 | $82.83 | $153,810.30 |
DisclosureSEC source: 0001562180-21-000288 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,943 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $82.53 to $83.50 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 17:15 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,700 | $81.98 | $139,359.54 |
DisclosureSEC source: 0001562180-21-000288 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,800 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.46 to $82.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 19:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001562180-20-007145 · primarydocument.xml · derivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,977 Underlying: Common Stock · 5,000 shares Expires 2029-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 19:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 859 | $65.49 | $56,258.83 |
DisclosureSEC source: 0001562180-20-007145 · primarydocument.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.37 to $65.65 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 19:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,141 | $64.73 | $268,039.48 |
DisclosureSEC source: 0001562180-20-007145 · primarydocument.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,359 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.25 to $65.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 19:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-20-007145 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2020 Filed Jan 11, 2021 17:15 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 5,000 | $0.46 | $2,285.00 |
DisclosureSEC source: 0001562180-21-000288 · primarydocument.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.